北美人工血液替代品市场,按产品类型(全氟碳 (PFC) 和基于血红蛋白的氧载体 (HBOC))、来源(人血、动物血、基于微生物的重组 HB、合成聚合物和干细胞)、应用(心血管疾病、恶性肿瘤、损伤、新生儿疾病、器官移植和产妇疾病)、最终用户(医院和诊所、血库等)、国家(美国、墨西哥)行业趋势和预测到 2028 年。
市场分析与洞察:北美人工血液替代品市场
预计人工血液替代品市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析,在 2021 年至 2028 年的预测期内,该市场以 26.4% 的复合年增长率增长,预计到 2028 年将达到 17,803.70 万美元。新鲜血液的供应有限及其短暂的寿命,再加上对输血的需求不断增加以及对血液替代品开发资金的增加,成为人工血液替代品市场增长的驱动力。
人工血液替代品又称为氧疗法或血红蛋白氧载体。它用于模拟生物血液的功能,并提供输血替代品。人工血液是替代库存红细胞输血的解决方案,旨在克服血液供应不足、高风险污染、交叉配血要求等局限性。同种异体输血具有多重风险,可导致传染病传播、输血反应、输血相关急性肺损伤、术后伤口愈合延迟、免疫调节和癌症复发的潜在风险。它为新的、重要的救命医疗方法带来了希望。
人造血液的来源包括动物血液、人类血液、微生物重组血红蛋白、干细胞等。人造血液还具有多种优于人类血液的优势,因为它属于通用血型,可以输给任何血型的患者。此外,人造血液替代品不会产生任何免疫反应。此外,人造血液替代品消除了输血过程中感染疾病或污染的风险,并且与人类血液相比,人造血液替代品的保质期更长,因为它可以在室温下保存 3 年或更长时间,而人类血液的保质期仅为 42 天。人造血液可用于紧急情况,并且易于储存,对于因宗教信仰而不接受献血的患者来说,人造血液也是完美的选择。
Limited availability of fresh blood and its short life span coupled with increasing demand for blood transfusion and increased funding for development of blood substitutes are the key factors driving the North America artificial blood substitutes market. However, the high cost production of artificial blood as well as stringent rules laid down by governmental bodies for approval of blood substitute products may hamper the growth of the artificial blood substitutes market. Also, rising awareness regarding the advantages offered by artificial blood and rising demand for artificial blood coupled with insufficient number of blood donor and growing number of research and development on artificial blood will create huge opportunities for the North America artificial blood substitutes market. The inavailability of artificial blood products, extended clinical trials and side effects associated with artificial blood will create a huge challenge for the North America artificial blood substitutes market.
The artificial blood substitutes market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the artificial blood substitutes market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Artificial blood substitutes Market Scope and Market Size
The artificial blood substitutes market is segmented on the based on the product type, source, application and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the North America artificial blood substitutes market is segmented into perflurocarbon (PFCs) and hemoglobin-based oxygen carries (HBOCs). Perflurocarbon (PFCs) is further segmented into perftoran. Hemoglobin-based oxygen carries (HBOCs) is further segmented into oxyglobin and hemopure. In 2021, the hemoglobin-based oxygen carries (HBOCs) segment is expected to dominate the artificial blood substitutes market due to rising demand for blood substitutes which eliminates the blood typing and to overcome the shortage of human blood.
- On the basis of source, the North America artificial blood substitutes market is segmented into human blood, animal blood, microorganism based recombinant HB, synthetic polymers and stem cells. In 2021, the animal blood segment is expected to dominate the artificial blood substitutes market due to availability of ample amount of source to produce artificial blood.
- 根据应用,北美人造血液替代品市场细分为心血管疾病、恶性肿瘤、伤害、新生儿疾病、器官移植和产妇疾病。2021 年,由于伤害、道路事故等发生率上升,以及对治疗这些疾病的人造血液的需求量很大,预计伤害领域将主导人造血液替代品市场。
- 根据最终用户,北美人造血液替代品市场分为医院和诊所、血库和其他。2021 年,由于患有各种疾病的患者数量不断增加,对血液的需求不断增长,预计医院和诊所部门将主导人造血液替代品市场。
人造血液替代品市场国家层面分析
对人工血液替代品市场进行了分析,并按上述国家、产品类型、来源、应用和最终用户提供了市场规模信息。
人工血液替代品市场报告涉及的国家包括美国、墨西哥。
由于患者人数增加导致输血需求增加,预计美国的产品类型细分市场将在 2021 年至 2028 年的预测期内以最高增长率增长。由于治疗患者人数增加所需的人体血液有限,墨西哥的产品类型细分市场占据市场主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
主要市场参与者不断增加的战略活动提高了人们对人工血液替代品的认识,从而推动了人工血液替代品市场的市场增长。
人造血液替代品市场还为您提供每个国家特定市场增长的详细市场分析。此外,它还提供有关市场参与者战略及其地理分布的详细信息。数据适用于 2010 年至 2019 年的历史时期。
竞争格局和人工血液替代品市场份额分析
人造血液替代品市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对人造血液替代品市场的关注有关。
从事人工血液替代品业务的主要公司包括 HEMARINA、Hemoglobin Oxygen Therapeutics LLC、KaloCyte, Inc.、LLC “Visusmed”、欧洲药品管理局、OPK Biotech LLC、NuvOx Pharma、Prolong Pharmaceuticals, LLC、Boston Therapeutics, Inc.、Aurum Biosciences、OXYVITA Inc、NanoBlood LLC 以及其他国内公司。DBMR 分析师了解竞争优势,并为每个竞争对手分别提供竞争分析。
全球各地的公司也纷纷展开扩张和融资活动,加速人工血液替代品市场的发展。
例如,
- 2020 年 11 月,Hemarina 发表了一份关于 M 101(一种用于治疗牙周炎的氧气转运蛋白)的抗炎和抗菌特性的科学报告。这项研究验证了 M 101 分子的质量,该分子源自海洋沙蚕的血红蛋白。
- 2020 年 6 月,KaloCyte, Inc. 从马里兰大学系统 (USM) 动力基金获得了 30 万美元的资金,用于开发 ErythroMer,这是一种合成的、仿生的红血球替代品。这笔资金帮助该公司以更快的速度开发 ErythroMer。
- 2020 年 5 月,KaloCyte, Inc. 获得了美国国立卫生研究院 (NIH) 颁发的 373,000 美元小企业创新研究 (SBIR) 第一阶段拨款。这笔拨款帮助该公司推进 KaloCyte 产品进行临床前安全性和有效性测试,以备进行人体试验。
市场参与者的合作、业务扩展、奖励和认可、合资企业等策略正在增强公司在人工血液替代品市场的影响力,这也为组织的利润增长带来了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PATENT ANALYSIS OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
5.1 DBMR ANALYSIS
5.2 COUNTRY-LEVEL ANALYSIS
5.3 YEARWISE ANALYSIS
6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN DEMAND FOR BLOOD TRANSFUSION
7.1.2 INCREASED FUNDING FOR PRODUCT DEVELOPMENT
7.1.3 RISE IN BLOOD-RELATED DISORDERS AND TRAUMA CASES
7.1.4 LIMITED AVAILABILITY OF FRESH BLOOD AND SMALL STORAGE PERIODS OF FRESH BLOOD
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATORY APPROVAL PROCESS
7.2.2 HIGH-COST PRODUCTION OF ARTIFICIAL BLOOD SUBSTITUTE
7.2.3 UNAWARENESS ABOUT THE ARTIFICIAL BLOOD SUBSTITUTES
7.3 OPPORTUNITIES
7.3.1 INCREASE IN AWARENESS REGARDING THE ADVANTAGES OF ARTIFICIAL BLOOD OVER HUMAN BLOOD
7.3.2 RISE IN DEMAND FOR BLOOD SUBSTITUTES AND INSUFFICIENT NUMBER OF BLOOD DONORS
7.3.3 RISE IN NUMBER OF RESEARCH & DEVELOPMENTS ON ARTIFICIAL BLOOD
7.3.4 AMPLE AMOUNT OF SOURCES FOR PRODUCTION OF ARTIFICIAL BLOOD SUBSTITUTE
7.4 CHALLENGES
7.4.1 INSTABILITY OF ARTIFICIAL BLOOD PRODUCT
7.4.2 EXTENDED CLINICAL TRAILS
7.4.3 SIDE EFFECTS OF ARTIFICIAL BLOOD SUBSTITUTES
8 IMPACT OF COVID-19 ON THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
8.1 AFTERMATH OF COVID-19
8.2 IMPACT ON SUPPLY AND DEMAND
8.3 THE INCREASING DEMAND FOR BLOOD TRANSFUSION IS LEADING THE ARTIFICIAL BLOOD SUBSTITUTES MARKET.
8.4 CONCLUSION
9 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS)
9.2.1 OXYGLOBIN
9.2.2 HEMOPURE
9.3 PERFLUOROCARBON (PFCS)
9.3.1 PERFTORAN
9.3.2 OTHERS
10 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE
10.1 OVERVIEW
10.2 ANIMAL BLOOD
10.3 HUMAN BLOOD
10.4 MICROORGANISM BASED RECOMBINANT HB
10.5 STEM CELLS
10.6 SYNTHETIC POLYMERS
11 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 INJURIES
11.3 CARDIOVASCULAR DISEASES
11.4 ORGAN TRANSPLANT
11.5 MATERNAL CONDITION
11.6 MALIGNANT NEOPLASMA
11.7 NEONATAL CONDITIONS
12 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL AND CLINICS
12.3 BLOOD BANKS
12.4 OTHERS
13 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 MEXICO
14 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT
16 COMPANY PROFILE
16.1 KALOCYTE, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 COMPANY SAHRE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 HEMARINA
16.2.1 COMPANY SNAPSHOT
16.2.2 COMPANY SHARE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 HEMOGLOBIN OXYGEN THERAPEUTICS LLC
16.3.1 COMPANY SNAPSHOT
16.3.2 COMPANY SHARE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 LLC “VISUSMED”
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 EUROPEAN MEDICINES AGENCY
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 AURUM BIOSCIENCES
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BOSTON THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 NANOBLOOD LLC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 NUVOX PHARMA
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 OPK BIOTECH LLC
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 OXYVITA INC
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 PROLONG PHARMACEUTICALS, LLC
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 2 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 3 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIERS (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 4 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 5 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 7 NORTH AMERICA ANIMAL BLOOD IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 8 NORTH AMERICA HUMAN BLOOD IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 9 NORTH AMERICA MICROORGANISM BASED RECOMBINANT HB IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 10 NORTH AMERICA STEM CELLS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 11 NORTH AMERICA SYNTHETIC POLYMERS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 12 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 13 NORTH AMERICA INJURIES IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 14 NORTH AMERICA CARDIOVASCULAR DISEASES IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 15 NORTH AMERICA ORGAN TRANSPLANT IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 16 NORTH AMERICA MATERNAL CONDITION IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 17 NORTH AMERICA MALIGNANT NEOPLASMA IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 18 NORTH AMERICA NEONATAL CONDITIONS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 19 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 20 NORTH AMERICA HOSPITALS AND CLINICS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 21 NORTH AMERICA BLOOD BANKS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 22 NORTH AMERICA OTHERS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 23 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)
TABLE 24 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 25 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 26 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 27 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 28 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 29 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 30 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 31 U.S. HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 32 U.S. PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 33 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 34 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 35 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 36 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 37 MEXICO HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 38 MEXICO PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 39 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 40 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 41 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SEGMENTATION
FIGURE 11 INCREASED DEMAND FOR BLOOD TRANSFUSION IS EXPECTED TO DRIVE THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 HAEMOGLOBIN-BASED OXYGEN CARRIERS (HBOCS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET IN 2021 & 2028
FIGURE 13 PATENT REGISTERED FOR ARTIFICIAL BLOOD SUBSTITUTES, BY COUNTRY
FIGURE 14 PATENT REGISTERED YEAR (2017 - 2021)
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
FIGURE 16 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2020
FIGURE 17 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2020
FIGURE 18 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2020
FIGURE 19 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2020
FIGURE 20 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SNAPSHOT (2020)
FIGURE 21 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2020)
FIGURE 22 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 23 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 24 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY PRODUCT TYPE (2021-2028)
FIGURE 25 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.